Anti-inflammatory Compounds

Following the 2014 FDA-approval of OTEZLA® (apremilast), Celgene is continuing to develop novel orally available small molecules that inhibit the production of multiple pro-inflammatory mediators.

Celgene is continuing to develop novel orally available small molecules that inhibit the production of multiple pro-inflammatory mediators.

This includes interleukin-2 (IL-2), IL-12, interferon-gamma, TNF-alpha, leukotrienes and nitric oxide synthase.